

NOVAVAX INC  
Form 8-K  
July 05, 2013

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported) July 2, 2013**

**NOVAVAX, INC.**

**(Exact name of Registrant as specified in its charter)**

**Delaware  
(State or other jurisdiction of incorporation or  
organization)**

**0-26770**

**22-2816046**

**(Commission File Number) (I.R.S. Employer Identification No.)**

**9920 Belward Campus Drive**

**20850**

**Rockville, Maryland**

**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code: (240) 268-2000**

**(Former name or former address, if changed since last report.)**

**Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):**

- “ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)**
- “ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)**
- “ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))**
- “ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))**

**Item 8.01. Other Events.**

On July 2, 2013, Novavax, Inc. (“Novavax”) issued a press release announcing that its RSV vaccine candidate was safe and immunogenic in elderly subjects 60 years or higher in age. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d)Exhibits

**Exhibits**

99.1	Press Release of Novavax, Inc. dated July 2, 2013
------	---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized

Novavax, Inc.  
(Registrant)

July 5, 2013    By:    /s/ John A. Herrmann III  
                  Name:    John A. Herrmann III  
                                  Vice President, General  
                  Title:    Counsel and  
                                  Corporate Secretary